Retinal Gene Therapy Market

By Indication;

Leber Congenital Amaurosis (LCA), Stargardt Disease, Choroideremia, X-linked Retinitis Pigmentosa (RP) and Others

By Application;

Adeno-Associated Virus, Lentivirus, Messenger RNA, and DNA

By End User;

Hospitals, Specialty Clinics,and Academic Research Institutes

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn222031891 Published Date: June, 2025 Updated Date: July, 2025

Retinal Gene Therapy Market Overview

Retinal Gene Therapy Market (USD Million)

Retinal Gene Therapy Market was valued at USD 111.35 million in the year 2024. The size of this market is expected to increase to USD 198.51 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.6%.


Retinal Gene Therapy Market

*Market size in USD million

CAGR 8.6 %


Study Period2025 - 2031
Base Year2024
CAGR (%)8.6 %
Market Size (2024)USD 111.35 Million
Market Size (2031)USD 198.51 Million
Market ConcentrationMedium
Report Pages338
111.35
2024
198.51
2031

Major Players

  • Gyroscope Therapeutics (Novartis)
  • Applied Genetic Technologies Corporation (AGTC)
  • Spark Therapeutics
  • Adverum Biotechnologies
  • REGENXBIO Inc.
  • Biogen Inc.
  • Nightstar Therapeutics
  • MeiraGTx Holdings plc

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Retinal Gene Therapy Market

Fragmented - Highly competitive market without dominant players


The Retinal Gene Therapy Market is growing as emerging therapies prove effective for inherited vision disorders. Around 35% of current treatments aim at rare genetic forms of blindness. These gene‑based interventions deliver corrected genetic material to retinal cells to restore functionality. Their clinical success is generating strong interest within ophthalmic research and clinical communities.

Enhanced Delivery Methods Driving Efficacy
Nearly 30% of R&D efforts now focus on advanced payload delivery, including refined injection techniques and nonviral vectors. These methods offer improved precision, reduced invasiveness, and enhanced durability. Biotech and academic institutions are co‑developing innovative platforms for better targeting. Improved delivery mechanisms increase patient safety and the likelihood of lasting vision improvement.

Collaborative Alliances Speed Progress
About 40% of development efforts involve collaborations between specialized biotech companies and established pharma partners. These alliances combine clinical trial infrastructure, regulatory insight, and commercialization reach. Joint initiatives also support diagnostic tools and long‑term patient management plans. Cooperations accelerate therapy timelines and improve healthcare integration.

Growth Strategies and Market Evolution
More than 45% of companies are targeting global trial expansion and planning therapy rollouts across multiple regions. Expansion plans include scaling manufacturing and developing post‑approval monitoring frameworks. Firms are broadening development into conditions such as diabetic retinopathy and macular degeneration. This strategic expansion is supported by ongoing innovation in vectorology and patient outreach.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Application
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Retinal Gene Therapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advanced genetic research
        2. Increasing clinical trials
        3. Rising retinal diseases
        4. Technological advancements rapidly
        5. Growing aging population
      2. Restraints
        1. High treatment costs
        2. Regulatory approval complexities
        3. Limited market awareness
        4. Shortage of specialists
        5. Insufficient Insurance Coverage
      3. Opportunities
        1. Emerging market expansion
        2. Enhanced diagnostic techniques
        3. Strategic industry collaborations
        4. Personalized medicine growth
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Retinal Gene Therapy Market, By Indication, 2021 - 2031 (USD Million)
      1. Leber Congenital Amaurosis (LCA)
      2. Stargardt Disease
      3. Choroideremia
      4. X-linked Retinitis Pigmentosa (RP)
      5. Others
    2. Retinal Gene Therapy Market, By Application, 2021 - 2031 (USD Million)

      1. Adeno-associated Virus

      2. Lentivirus

      3. Messenger RNA

      4. DNA

    3. Retinal Gene Therapy Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Academic Research Institutes
    4. Retinal Gene Therapy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa

        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Gyroscope Therapeutics (Novartis)
      2. Applied Genetic Technologies Corporation (AGTC)
      3. Spark Therapeutics
      4. Adverum Biotechnologies
      5. REGENXBIO Inc.
      6. Biogen Inc.
      7. Nightstar Therapeutics
  7. Analyst Views
  8. Future Outlook of the Market